Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | KLK5 | Q9Y337 | 7/20 | 0.42 |
| ▸ | KLK7 | P49862 | 7/20 | 0.42 |
| ▸ | BCHE | P06276 | 4/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31614132 | 0.83 | KMT2A (0.47) | KMT2AL3MBTL1KLK5KLK7KDM1A | |
| SCHEMBL31200867 | 0.83 | KMT2A (0.47) | KMT2AL3MBTL1KLK5KLK7KDM1A | |
| SCHEMBL31200587 | 0.83 | KMT2A (0.47) | KMT2AL3MBTL1KLK5KLK7KDM1A | |
| SCHEMBL31470310 | 0.81 | KMT2A (0.52) | KMT2AL3MBTL1KLK5KLK7KDM1A | |
| SCHEMBL3830180 | 0.81 | KMT2A (0.60) | KMT2AL3MBTL1KLK5KLK7KDM1A | |
| SCHEMBL3830184 | 0.81 | KMT2A (0.60) | KMT2AL3MBTL1KLK5KLK7KDM1A | |
| SCHEMBL9430749 | 0.81 | KMT2A (0.60) | KMT2AL3MBTL1KLK5KLK7KDM1A | |
| SCHEMBL23185762 | 0.79 | KMT2A (0.50) | KMT2AL3MBTL1KLK5KLK7KDM1A | |
| SCHEMBL30143734 | 0.79 | KMT2A (0.50) | KMT2AL3MBTL1KLK5KLK7KDM1A | |
| SCHEMBL19863570 | 0.78 | KMT2A (0.47) | KMT2AL3MBTL1KLK5KLK7KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680601-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | Sanofi (FR) | 2026-01-21 | — | — | EP | disclosed |
| US-20240360151-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | SANOFI (FR) | 2024-10-31 | — | — | US | disclosed |
| WO-2024188994-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | SANOFI (FR) | 2024-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360151-A1 | PYRIDAZINE COMPOUNDS, THEIR PREPARATION, AND THEIR THERAPEUTIC USES | NLRP3, NOD1, NLRP1 | KMT2A 4589/4885L3MBTL1 3872/4885KLK5 3860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.